Provided by Tiger Trade Technology Pte. Ltd.

ARS PHARMACEUTICALS INC

4.76
-0.3000-5.93%
Post-market: 4.890.1300+2.73%19:43 EDT
Volume:2.57M
Turnover:12.57M
Market Cap:473.37M
PE:-2.19
High:5.19
Open:5.13
Low:4.73
Close:5.06
52wk High:13.15
52wk Low:4.73
Shares:99.45M
Float Shares:48.03M
Volume Ratio:2.58
T/O Rate:5.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1757
EPS(LYR):-1.7400
ROE:-210.35%
ROA:-48.02%
PB:37.83
PE(LYR):-2.74

Loading ...

ARS Pharmaceuticals is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 26

ARS Pharma Tumbles as Allergy Nasal Spray Faces Insurance Coverage Hurdle

Reuters
·
Jun 25

Top Premarket Decliners

MT Newswires Live
·
Jun 25

Stocks to Watch: Micron, ARS Pharmaceuticals, Millerknoll, Passage Bio

Dow Jones
·
Jun 25

Shares of ARS Pharmaceuticals Fall After no New Commercial Insurers Add Neffy

Dow Jones
·
Jun 25

ARS reports no new commercial formulary additions, coverage decisions for neffy

TIPRANKS
·
Jun 25

ARS Pharma Cuts 2026 Cash Operating Expense Outlook to $248 Million Excluding COGS

Reuters
·
Jun 25

ARS Pharmaceuticals Inc: Total 2026 Cash-based Operating Expenses, Excluding Cogs, Lowered to $248 Mln

THOMSON REUTERS
·
Jun 25

ARS Pharmaceuticals Inc: Reaffirms Neffy Base Business Supports a Path to Cash-flow Breakeven in 2027

THOMSON REUTERS
·
Jun 25

ARS Pharmaceuticals - no New Commercial Formulary Additions for Neffy in July 1, 2026 Cycle

THOMSON REUTERS
·
Jun 25

ARS Pharmaceuticals Provides Commercial and Financial Updates

THOMSON REUTERS
·
Jun 25

ARS Pharma Chief Commercial Officer Eric Karas sells 25,000 shares for $250,000

Reuters
·
Jun 13

ARS Pharma Chief Legal Officer Alexander Fitzpatrick sells 3,355 shares for $33,550

Reuters
·
Jun 13

Drew Brees Collaborates With ARS Pharmaceuticals to Raise Awareness About Living Life With Severe Allergies

THOMSON REUTERS
·
Jun 04

ARS Pharmaceuticals files Form 3 for President Donn Casale, reporting no beneficial ownership

Reuters
·
Jun 02

ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
May 28

ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

BUZZ-U.S. STOCKS ON THE MOVE-Cerebras, Papa John's, airline stocks

Reuters
·
May 15

ARS Pharma Q1 FY26 net loss widens to $60.62 million; revenue more than doubled to $22.68 million

Reuters
·
May 15

ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell

MT Newswires Live
·
May 15